Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI =27 kg/m2

Sotagliflozin, a dual SGLT1/SGLT2 inhibitor, is currently approved in Europe as an adjunct to optimal insulin therapy in adults with type 1 diabetes (T1D) and a body mass index (BMI) =27 kg/m2. In this post hoc analysis, efficacy at 24weeks and safety at 52weeks from pooled phase 3 clinical trials were evaluated in patients with baseline BMI =27 kg/m2. Sotagliflozin 200 and 400 mg added to insulin reduced HbA1c and increased time-in-range by continuous glucose monitoring vs placebo and also reduced body weight and systolic blood pressure. Differences in efficacy endpoints between sotagliflozin and placebo tended to be greater among patients with BMI =27 kg/m2 compared to those with baseline BMI